BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 10389757)

  • 1. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
    Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
    Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity.
    Azuma A; Hanaoka K; Kurihara A; Kobayashi T; Miyauchi S; Kamo N; Tanaka M; Sasaki T; Matsuda A
    J Med Chem; 1995 Aug; 38(17):3391-7. PubMed ID: 7650692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and biochemical characterization of a 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080.
    Obata T; Endo Y; Tanaka M; Matsuda A; Sasaki T
    Cancer Lett; 1998 Jan; 123(1):53-61. PubMed ID: 9461018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Design of a new antitumor nucleoside CNDAC, against solid tumors].
    Matsuda A
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):202-10. PubMed ID: 8611048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
    Liu XJ; Nowak B; Wang YQ; Plunkett W
    Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
    Iizuka K; Zhang C; Eshima K; Jin C; Eshima K; Fukushima M
    Int J Oncol; 2018 Mar; 52(3):851-860. PubMed ID: 29344636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
    Azuma A; Huang P; Matsuda A; Plunkett W
    Mol Pharmacol; 2001 Apr; 59(4):725-31. PubMed ID: 11259616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
    Matsuda A; Nakajima Y; Azuma A; Tanaka M; Sasaki T
    J Med Chem; 1991 Sep; 34(9):2917-9. PubMed ID: 1895307
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors.
    Tanaka M; Matsuda A; Terao T; Sasaki T
    Cancer Lett; 1992 May; 64(1):67-74. PubMed ID: 1596880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
    Azuma A; Nakajima Y; Nishizono N; Minakawa N; Suzuki M; Hanaoka K; Kobayashi T; Tanaka M; Sasaki T; Matsuda A
    J Med Chem; 1993 Dec; 36(26):4183-9. PubMed ID: 8277499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
    Delaunoit T; Burch PA; Reid JM; Camoriano JK; Kobayash T; Braich TA; Kaur JS; Rubin J; Erlichman C
    Invest New Drugs; 2006 Jul; 24(4):327-33. PubMed ID: 16502355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model.
    Wu M; Mazurchuk R; Chaudhary ND; Spernyak J; Veith J; Pera P; Greco W; Hoffman RM; Kobayashi T; Bernacki RJ
    Cancer Res; 2003 May; 63(10):2477-82. PubMed ID: 12750269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC).
    Azuma A; Huang P; Matsuda A; Plunkett W
    Biochem Pharmacol; 2001 Jun; 61(12):1497-507. PubMed ID: 11377379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of sugar-modified cytosine nucleosides.
    Matsuda A; Sasaki T
    Cancer Sci; 2004 Feb; 95(2):105-11. PubMed ID: 14965358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides.
    Obata T; Endo Y; Tanaka M; Uchida H; Matsuda A; Sasaki T
    Jpn J Cancer Res; 2001 Jul; 92(7):793-8. PubMed ID: 11473731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.
    Liu X; Jiang Y; Nowak B; Hargis S; Plunkett W
    Mol Cancer Ther; 2016 Oct; 15(10):2302-2313. PubMed ID: 27474148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
    Liu X; Jiang Y; Nowak B; Qiang B; Cheng N; Chen Y; Plunkett W
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):255-267. PubMed ID: 29189915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine with gemcitabine in its antitumor activity.
    Miura S; Yoshimura Y; Endo M; Satoh H; Machida H; Sasaki T
    Cancer Lett; 1999 Oct; 144(2):177-82. PubMed ID: 10529018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants in chemosensitivity of oncogene-transformed NIH3T3 cells to 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine.
    Zhang M; Endo Y; Sasaki T
    Int J Oncol; 1999 Mar; 14(3):543-9. PubMed ID: 10024689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.